Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs

Why Is There No Food and Drug Administration–Approved Medication for Major Depression With Psychotic Features?: Psychotic depression is a severely disabling illness and is more common than is generally realized. Unfortunately, there is no FDA-approved medication for its treatment. In this podcast, the Editor-in-Chief of the Journal of Clinical... by The Journal of Clinical Psychopharmacology Podcast

12 min listen

Time to reconsider monoamine oxidase inhibitors (MAOIs) for Obsessive Compulsive Disorder? A case series using phenelzine: Obsessive compulsive disorder (OCD) can often be effectively treated with cognitive behavioral therapy or serotonin reuptake inhibitors. About one-third of patients, however, do not receive adequate symptom relief. Jon E. Grant discusses the potential... by The Journal of Clinical Psychopharmacology Podcast

7 min listen

The Pitfalls of Psychotropic Polypharmacy: Editor-in-Chief Anthony Rothschild discusses his editorial, “The Pitfalls of Psychotropic Polypharmacy.” For psychiatric disorders, it is common for patients to be prescribed more than one medication. While there may be benefits, it is essential... by The Journal of Clinical Psychopharmacology Podcast

8 min listen

The Placenta and Psychiatry?: Dr. Julia Ann Koretski reflects on the critical role of the placenta in drug metabolism and potential near- and long-term effects on postanatal life. The placenta was once viewed as a passive, almost mechanical barrier, but we are continuing to learn... by The Journal of Clinical Psychopharmacology Podcast

6 min listen

Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers: Authors Nicholas A. Mischel and Richard Balon discuss their commentary, “Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers.” Their commentary asks: How does this treatment fit into the broader repertoire in... by The Journal of Clinical Psychopharmacology Podcast

8 min listen

Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs: A large observational study from researchers at Washington University in St. Louis found an elevated risk of breast cancer in women who take some types of antipsychotic drugs – specifically, drugs that raise levels of the hormone prolactin. In this... by The Journal of Clinical Psychopharmacology Podcast

12 min listen

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior: Individuals with major depressive disorder and suicidal ideation are particularly vulnerable and may not respond as well to standard treatment as patients without suicidal ideation. In this author podcast, Dr. Dong-Jing Fu and Dr. Carla Canuso discuss... by The Journal of Clinical Psychopharmacology Podcast

7 min listen

Should Antipsychotic Medications Be Prescribed to Patients with Nonpsychotic Depression?: In this podcast, Editor-in-Chief Anthony Rothschild discusses his editorial in the May-June 2022 issue about the use of antipsychotic medications for treatment of nonpsychotic patients. With four drugs approved by the FDA for use as augmentation for... by The Journal of Clinical Psychopharmacology Podcast

12 min listen

Calcium Channel Antagonists for Mood Disorders: Drs. Steve Dubovsky and Dori Marshall discuss their article reviewing the potential of calcium channel blockers for the treatment of mood disorders, an area of research that the authors assert has received too little attention. Their article, titled... by The Journal of Clinical Psychopharmacology Podcast

17 min listen

Domestic Mass Shooters: The Association With Unmedicated and Untreated Psychiatric Illness: Mass shootings have become a common occurrence in the United States and elsewhere. In this podcast, author Ira D. Glick discusses the research he and his colleagues conducted to analyze whether certain mass shooters had psychiatric illnesses and had... by The Journal of Clinical Psychopharmacology Podcast

7 min listen

Lifetime cannabis use disorder is not associated with lifetime impulsive behavior and severe violence in patients with schizophrenia spectrum disorders from a high-security hospital: The link between substance abuse, impulsivity, and violence in psychotic patients remains unclear. In this author podcast, Gabriella Gobbi, MD, PhD, and Stefano Comai, PhD, discuss their study, which was designed to assess whether cannabis use... by The Journal of Clinical Psychopharmacology Podcast

23 min listen

Are the same medications that are used in the acute treatment of depression the most suitable for preventing relapse?: In the effort to prevent relapse in patients who have experienced depressive episodes, it has been common practice to have them continue long-term on antidepressant medications, including selective serotonin reuptake inhibitors (SSRIs) and serotonin... by The Journal of Clinical Psychopharmacology Podcast

8 min listen

Anosognosia and Psychosis: More Research is Needed on How Best to Treat People Unaware of Their Disorder: Among individuals with schizophrenia, an estimated 50% to 80% have a partial or even total lack of insight into the presence of their mental disorder. This condition, known as anosognosia, has also been observed in people with other diagnoses, such as... by The Journal of Clinical Psychopharmacology Podcast

42 min listen

Panic Disorder Seeks More Specific Drugs for Treatment : Might the Amygdala Be the Best Target?: Panic disorder is a common psychiatric disorder, with generally effective pharmacologic treatments for most patients. However, a subset of patients do not respond, and roughly 25% of patients have adverse effects. In this podcast, based on his... by The Journal of Clinical Psychopharmacology Podcast

9 min listen

Structured Interventions to Optimize Polypharmacy in Psychiatric Treatment and Nursing Homes: A Systematic Review: “Polypharmacy,” the simultaneous use of multiple medications, has been linked to an increased risk of treatment complications. An article in the March-April 2022 issue of the Journal of Clinical Psychopharmacology takes a systematic look at... by The Journal of Clinical Psychopharmacology Podcast

11 min listen

Raising the Quality of Psychopharmacology Care: How can we improve psychopharmacology practice? This podcast features a lively discussion among the authors of two articles in the January-February 2022 issue of the Journal of Clinical Psychopharmacology in which they address that important topic.... by The Journal of Clinical Psychopharmacology Podcast

31 min listen

Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents: The use of the combination of stimulants and antipsychotic medications is increasing in pediatric patients who suffer from Attention Hyperactivity Disorder (ADHD). In this podcast, Dr. Mohamed Mohamoud discusses how this combination may result in... by The Journal of Clinical Psychopharmacology Podcast

11 min listen

Effects of Selective Serotonin Reuptake Inhibitor Use on MDMA–Assisted Therapy for Posttraumatic Stress Disorder: In small-scale studies, 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder has shown some promise, but exploratory analyses have suggested that recent use of selective serotonin reuptake inhibitors (SSRIs) can... by The Journal of Clinical Psychopharmacology Podcast

12 min listen

Unfair Criticisms of Psychopharmacology: A recently published book provides sharp criticism of the modern era of clinical psychopharmacology, questioning the validity of psychiatric diagnoses and the effectiveness of psychopharmacologic treatments. In this podcast, Dr. Anthony J. Rothschild,... by The Journal of Clinical Psychopharmacology Podcast

7 min listen

Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series: Clozapine is often prescribed for patients with treatment-resistant schizophrenia, but its use is sometimes discontinued if it is suspected of inducing neutropenia. In this podcast, author Laurent Béchard discusses a consecutive case series... by The Journal of Clinical Psychopharmacology Podcast

10 min listen

Exposure to SARS-CoV-2, Acute Kidney Injury, and Lithium Toxicity: In this podcast, Dr. Melvin McInnis discusses lithium toxicity in individuals with bipolar disorder who were infected by the SARS-CoV-2 virus. Lithium is an effective long-term management strategy for treating bipolar disorder, but because acute... by The Journal of Clinical Psychopharmacology Podcast

6 min listen

Psychedelics in the Treatment of Depression: A Critical Appraisal of Evidence: Psychedelics as a potential treatment for depression is an irresistible topic in the mainstream press, but what is the evidence base for their use? In this podcast, psychiatrist and journal Digital Editor Dr. Julia Ann Koretski (of Mass General... by The Journal of Clinical Psychopharmacology Podcast

24 min listen

The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward: In this podcast, Dr. Jonathan Leung discusses the article, “The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward,” published with several colleagues in the November-December 2022 issue of the... by The Journal of Clinical Psychopharmacology Podcast

13 min listen

Celebrating 70 Years of the First Publication on Antipsychotic Treatment in North America by Heinz E. Lehmann and Gorman E. Hanrahan: Would Their Methodology Still Be Conceivable?: In 1954, Dr Heinz Lehmann published the first clinical article on the use of chlorpromazine. Chlorpromazine was the first synthetic drug used to control states of mania and psychomotor excitement, marking the birth of modern psychopharmacology.... by The Journal of Clinical Psychopharmacology Podcast

32 min listen

Real-World Clinical Practice Among Patients With Bipolar Disorder and Chronic Kidney Disease on Long-term Lithium Therapy: Lithium is considered a standard treatment for bipolar disorder, but it remains underprescribed, in part because of its association with kidney dysfunction. In this podcast, Dr. Balwinder Singh discusses on “real-world” clinical practice... by The Journal of Clinical Psychopharmacology Podcast

8 min listen

Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia: Clozapine is a unique antipsychotic with superior efficacy in treatment-resistant schizophrenia (TRS). Unfortunately, approximately 40% to 70% of patients on clozapine continue to experience psychotic symptoms. Nevertheless, there is a concern about... by The Journal of Clinical Psychopharmacology Podcast

13 min listen

κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine: For individuals with treatment-resistant depression, ketamine can be an effective fast-acting alternative to conventional antidepressants. It has been hypothesized that it partly exerts its antidepressant effects by modulating the opioid system. In... by The Journal of Clinical Psychopharmacology Podcast

6 min listen

The Need for Examining the Role of Psychostimulants in Treatment of Methamphetamine Use/Dependence: Replacement therapy is a key tool in the treatment of individuals who abuse opioids. The idea is to replace heroin or morphine with less euphoric and longer-acting substances, such as methadone, under a medication management protocol. The goals of... by The Journal of Clinical Psychopharmacology Podcast

10 min listen

Artificial Intelligence and the Journal of Clinical Psychopharmacology: Much has been written in recent months regarding the growing use of artificial intelligence (AI) in medicine and the potential benefits and risks of its use. In this podcast, Anthony J. Rothschild, MD, Editor-in-Chief of the Journal of Clinical... by The Journal of Clinical Psychopharmacology Podcast

8 min listen

Valproic Acid–Associated Hyperammonemia: A Systematic Review: Hyperammonemia is an adverse effect that poses clinical uncertainty regarding the prescription of valproic acid (VPA) use. The prevalence of symptomatic and asymptomatic hyperammonemia and its relationship to VPA concentration is not well established.... by The Journal of Clinical Psychopharmacology Podcast

13 min listen

Discover this podcast and so much more

Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs

Description

Titles in the series (41)

More Episodes from The Journal of Clinical Psychopharmacology Podcast

Related podcast episodes